Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model

Yazir, Yusufhan; KILICOGLU, Erhan; YAVUZ, Ayse Nur HAZAR; KABATAŞ, GÜl Sinemcan; Kabasakal, Levent

doi:10.29228/jrp.447

Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model

Erhan KILICOGLU, (Marmara Üniversitesi, Eczacılık Fakültesi, Eczacılık Anabilim Dalı, İstanbul, Türkiye)

Ayse Nur HAZAR YAVUZ, (Marmara Üniversitesi, Eczacılık Fakültesi, Eczacılık Anabilim Dalı, İstanbul, Türkiye)

GÜl Sinemcan KABATAŞ, (Kocaeli Üniversitesi, Tıp Fakültesi, Kök Hücre ve Gen Tedavileri Araştırma ve Uygulama Merkezi, Kocaeli, Türkiye)

Yusufhan YAZIR, (Kocaeli Üniversitesi, Tıp Fakültesi, Kök Hücre ve Gen Tedavileri Araştırma ve Uygulama Merkezi, Kocaeli, Türkiye)

Levent KABASAKAL (Marmara Üniversitesi, Eczacılık Fakültesi, Eczacılık Anabilim Dalı, İstanbul, Türkiye)

Journal of research in pharmacy (online)

29 0

Yıl: 2023 Cilt: 27 Sayı: 4 Sayfa Aralığı: 1626 - 1637 Metin Dili: İngilizce DOI: 10.29228/jrp.447 İndeks Tarihi: 28-07-2023

Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model

Öz:

Inflammatory bowel disease (IBD) is a complex disease with an incompletely understood multifactorial etiopathogenesis. The importance of intestinal microbiota in IBD and the role of probiotics in the treatment are being extensively investigated. This study evaluated the therapeutic effects of Bifidobacterium animalis subsp. lactis BB-12, Lactobacillus reuteri, Saccharomyces boulardii and Bacillus clausii in trinitrobenzene sulfonic acid (TNBS)-induced colitis animal model. Rats were randomly grouped into 7: control, colitis, colitis+BB-12, colitis+L. reuteri, colitis+S. boulardii, colitis+B. clausii and colitis+methylprednisolone (positive control) treatment groups. Colitis was induced by the administration of intracolonically 80 mg/kg TNBS. Treatments continued for 7 days. Body weight, stool consistency, rectal bleeding, and disease activity index (DAI) scores were evaluated and recorded daily. Macroscopic and microscopic colonic damage were evaluated and scored in the last day of experiment. Levels of malondialdehyde (MDA) and (GSH) and activity of myeloperoxidase (MPO) in the colonic tissues were detected by ELISA. Our results showed that treatments with BB-12, L. reuteri, S. boulardii and B. clausii significantly improved on clinical symptoms and decreased macroscopic and microscopic colonic damage on experimental colitis in rats. In addition, L. reuteri and S. boulardii significantly increased GSH levels and decreased MDA levels and MPO activity. When we evaluate our findings, we think that supplements of these specific probiotics may have beneficial effects in the treatment of IBD.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020 Jan;5(1):17-30. https://doi.org/10.1016/S2468-1253(19)30333-4
2. Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014 Jan 7;20(1):91-9. https://doi.org/10.3748/wjg.v20.i1.91
3. Revés J, Ungaro RC, Torres J. Unmet needs in inflammatory bowel disease. Curr Res Pharmacol Drug Discov. 2021 Nov 30;2:100070. https://doi.org/10.1016/j.crphar.2021.100070
4. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017 Apr 29;389(10080):1741-1755. https://doi.org/10.1016/S0140-6736(16)31711-1
5. Du L, Ha C. Epidemiology and Pathogenesis of Ulcerative Colitis. Gastroenterol Clin North Am. 2020 Dec;49(4):643- 654. https://doi.org/10.1016/j.gtc.2020.07.005
6. Molnar T, Annaházi A (2014) Pathogenesis of Ulcerative Colitis and Crohn’s Disease: Similarities, Differences and a Lot of Things We Do Not Know Yet. J Clin Cell Immunol 5: 253. https://doi.org/10.4172/2155-9899.1000253
7. Rosen MJ, Dhawan A, Saeed SA. Inflammatory Bowel Disease in Children and Adolescents. JAMA Pediatr. 2015 Nov;169(11):1053-60. https://doi.org/10.1001/jamapediatrics.2015.1982
8. Younis N, Zarif R, Mahfouz R. Inflammatory bowel disease: between genetics and microbiota. Mol Biol Rep. 2020 Apr;47(4):3053-3063. https://doi.org/10.1007/s11033-020-05318-5
9. Hill, C., Guarner, F., Reid, G. et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11, 506–514 (2014). https://doi.org/10.1038/nrgastro.2014.66
10. Yeşilyurt, N.; Yılmaz, B.; Ağagündüz, D.; Capasso, R. Involvement of Probiotics and Postbiotics in the Immune System Modulation. Biologics 2021, 1, 89-110. https://doi.org/10.3390/biologics1020006
11. Kim SK, Guevarra RB, Kim YT, Kwon J, Kim H, Cho JH, Kim HB, Lee JH. Role of Probiotics in Human Gut Microbiome-Associated Diseases. J Microbiol Biotechnol. 2019 Sep 28;29(9):1335-1340. https://doi.org/10.4014/jmb.1906.06064
12. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017 Dec 23;390(10114):2769-2778. https://doi.org/10.1016/S0140-6736(17)32448-0
13. Zhao M, Gönczi L, Lakatos PL, Burisch J. The Burden of Inflammatory Bowel Disease in Europe in 2020. J Crohns Colitis. 2021 Sep 25;15(9):1573-1587. https://doi.org/10.1093/ecco-jcc/jjab029
14. Tian T, Wang Z, Zhang J. Pathomechanisms of Oxidative Stress in Inflammatory Bowel Disease and Potential Antioxidant Therapies. Oxid Med Cell Longev. 2017;2017:4535194. https://doi.org/10.1155/2017/4535194
15. Cai Z, Wang S, Li J. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Front Med (Lausanne). 2021 Dec 20;8:765474. https://doi.org/10.3389/fmed.2021.765474
16. McFarland LV, Evans CT, Goldstein EJC. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2018 May 7;5:124. https://doi.org/10.3389/fmed.2018.00124
17. Kilicoglu E. Prebiotics and Probiotics. In: Sener G, Goren ZM, Okuyan B, Yegen CB. (Eds). Güncel Farmakoloji Fizyoloji Temelinde Hasta Odaklı Yaklaşım, Güneş Kitabevi, Ankara, 2022, pp. 894-897
18. Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs. 2012 Apr 16;72(6):803-23. https://doi.org/10.2165/11632710-000000000-00000
19. Martyniak A, Medyńska-Przęczek A, Wędrychowicz A, Skoczeń S, Tomasik PJ. Prebiotics, Probiotics, Synbiotics, Paraprobiotics and Postbiotic Compounds in IBD. Biomolecules. 2021 Dec 18;11(12):1903. https://doi.org/10.3390/biom11121903
20. Wang Y, Wu Y, Wang Y, Xu H, Mei X, Yu D, Wang Y, Li W. Antioxidant Properties of Probiotic Bacteria. Nutrients. 2017 May 19;9(5):521. https://doi.org/10.3390/nu9050521
21. Antoniou E, Margonis GA, Angelou A, Pikouli A, Argiri P, Karavokyros I, Papalois A, Pikoulis E. The TNBSinduced colitis animal model: An overview. Ann Med Surg (Lond). 2016 Aug 19;11:9-15. https://doi.org/10.1016/j.amsu.2016.07.019
22. Silva I, Solas J, Pinto R, Mateus V. Chronic Experimental Model of TNBS-Induced Colitis to Study Inflammatory Bowel Disease. Int J Mol Sci. 2022 Apr 25;23(9):4739. https://doi.org/10.3390/ijms23094739
23. Dodda D, Chhajed R, Mishra J, Padhy M. Targeting oxidative stress attenuates trinitrobenzene sulphonic acid induced inflammatory bowel disease like symptoms in rats: role of quercetin. Indian J Pharmacol. 2014 May- Jun;46(3):286-91. https://doi.org/10.4103/0253-7613.132160
24. Kim JJ, Shajib MS, Manocha MM, Khan WI. Investigating intestinal inflammation in DSS-induced model of IBD. J Vis Exp. 2012 Feb 1;(60):3678. https://doi.org/10.3791/3678
25. Javed NH, Alsahly MB, Khubchandani J. Oral Feeding of Probiotic Bifidobacterium infantis: Colonic Morphological Changes in Rat Model of TNBS-Induced Colitis. Scientifica (Cairo). 2016;2016:9572596. https://doi.org/10.1155/2016/9572596
26. Satish Kumar CS, Kondal Reddy K, Boobalan G, Gopala Reddy A, Sudha Rani Chowdhary CH, Vinoth A, Jayakanth K, Srinivasa Rao G. Immunomodulatory effects of Bifidobacterium bifidum 231 on trinitrobenzenesulfonic acidinduced ulcerative colitis in rats. Res Vet Sci. 2017 Feb;110:40-46. https://doi.org/10.1016/j.rvsc.2016.10.010
27. Utku OG, Karatay E, Ergul B, Yılmaz C, Ekinci O, Arhan M. Is the Probiotic Mixture Effective in the Treatment of TNBS-induced Experimental Colitis? JAREM 2020;10(1): 41-7. https://doi.org/10.4274/jarem.galenos.2019.2247
28. Chen LL, Wang XH, Cui Y, Lian GH, Zhang J, Ouyang CH, Lu FG. Therapeutic effects of four strains of probiotics on experimental colitis in mice. World J Gastroenterol. 2009 Jan 21;15(3):321-7. https://doi.org/10.3748/wjg.15.321
29. Jakubczyk D, Leszczyńska K, Górska S. The Effectiveness of Probiotics in the Treatment of Inflammatory Bowel Disease (IBD)-A Critical Review. Nutrients. 2020 Jul 2;12(7):1973. https://doi.org/10.3390/nu12071973
30. Wilkins T, Sequoia J. Probiotics for Gastrointestinal Conditions: A Summary of the Evidence. Am Fam Physician. 2017 Aug 1;96(3):170-178. PMID: 28762696
31. Sha S, Xu B, Kong X, Wei N, Liu J, Wu K. Preventive effects of Escherichia coli strain Nissle 1917 with different courses and different doses on intestinal inflammation in murine model of colitis. Inflamm Res. 2014 Oct;63(10):873- 83. https://doi.org/10.1007/s00011-014-0761-1
32. Soyturk M, Saygili SM, Baskin H, Sagol O, Yilmaz O, Saygili F, Akpinar H. Effectiveness of Saccharomyces boulardii in a rat model of colitis. World J Gastroenterol. 2012 Nov 28;18(44):6452-60; discussion p. 6459. https://doi.org/10.3748/wjg.v18.i44.6452
33. Ackerman Z, Karmeli F, Cohen P, Rachmilewitz D. Experimental colitis in rats with portal hypertension and liver disease. Inflamm Bowel Dis. 2003 Jan;9(1):18-24. https://doi.org/10.1097/00054725-200301000-00003

APA	KILICOGLU E, YAVUZ A, KABATAŞ G, Yazir Y, Kabasakal L (2023). Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model. , 1626 - 1637. 10.29228/jrp.447
Chicago	KILICOGLU Erhan,YAVUZ Ayse Nur HAZAR,KABATAŞ GÜl Sinemcan,Yazir Yusufhan,Kabasakal Levent Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model. (2023): 1626 - 1637. 10.29228/jrp.447
MLA	KILICOGLU Erhan,YAVUZ Ayse Nur HAZAR,KABATAŞ GÜl Sinemcan,Yazir Yusufhan,Kabasakal Levent Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model. , 2023, ss.1626 - 1637. 10.29228/jrp.447
AMA	KILICOGLU E,YAVUZ A,KABATAŞ G,Yazir Y,Kabasakal L Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model. . 2023; 1626 - 1637. 10.29228/jrp.447
Vancouver	KILICOGLU E,YAVUZ A,KABATAŞ G,Yazir Y,Kabasakal L Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model. . 2023; 1626 - 1637. 10.29228/jrp.447
IEEE	KILICOGLU E,YAVUZ A,KABATAŞ G,Yazir Y,Kabasakal L "Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model." , ss.1626 - 1637, 2023. 10.29228/jrp.447
ISNAD	KILICOGLU, Erhan vd. "Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model". (2023), 1626-1637. https://doi.org/10.29228/jrp.447

APA	KILICOGLU E, YAVUZ A, KABATAŞ G, Yazir Y, Kabasakal L (2023). Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model. Journal of research in pharmacy (online), 27(4), 1626 - 1637. 10.29228/jrp.447
Chicago	KILICOGLU Erhan,YAVUZ Ayse Nur HAZAR,KABATAŞ GÜl Sinemcan,Yazir Yusufhan,Kabasakal Levent Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model. Journal of research in pharmacy (online) 27, no.4 (2023): 1626 - 1637. 10.29228/jrp.447
MLA	KILICOGLU Erhan,YAVUZ Ayse Nur HAZAR,KABATAŞ GÜl Sinemcan,Yazir Yusufhan,Kabasakal Levent Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model. Journal of research in pharmacy (online), vol.27, no.4, 2023, ss.1626 - 1637. 10.29228/jrp.447
AMA	KILICOGLU E,YAVUZ A,KABATAŞ G,Yazir Y,Kabasakal L Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model. Journal of research in pharmacy (online). 2023; 27(4): 1626 - 1637. 10.29228/jrp.447
Vancouver	KILICOGLU E,YAVUZ A,KABATAŞ G,Yazir Y,Kabasakal L Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model. Journal of research in pharmacy (online). 2023; 27(4): 1626 - 1637. 10.29228/jrp.447
IEEE	KILICOGLU E,YAVUZ A,KABATAŞ G,Yazir Y,Kabasakal L "Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model." Journal of research in pharmacy (online), 27, ss.1626 - 1637, 2023. 10.29228/jrp.447
ISNAD	KILICOGLU, Erhan vd. "Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model". Journal of research in pharmacy (online) 27/4 (2023), 1626-1637. https://doi.org/10.29228/jrp.447